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Abstract
The Cost-effectiveness of Alternative HIV Intervention Portfolios in South Africa. Robert
Stavert and Elisa Long (Sponsored by David Paltiel). Department of Epidemiology and
Public Health, Yale University, School of Medicine, New Haven, Ct.

A dynamic compartmental model was instantiated with recent epidemiological data from
South Africa to compare the effectiveness and cost-effectiveness of different portfolios of
interventions to prevent HIV infection over a twenty year time horizon. We hypothesized
that portfolios which combined scaling up the delivery of highly active antiretroviral
therapies (HAART), increasing availability of HIV screening and counseling, and
establishing widespread circumcision campaigns would be the most effective and most
cost-effective strategies. Portfolios which utilized widespread circumcision for adult men
were found to be the most cost-effective, while portfolios which utilized a combination of
interventions were found to be the most effective, in terms of quality adjusted life years
(QALYs) gained. These findings highlight the urgency of scaling up access to life-saving
antiretroviral treatments, and providing concomitant investments in HIV prevention and
testing programs in a generalized HIV epidemic setting such as South Africa.
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1. Introduction
1.1 HIV in South Africa
South Africa remains one of the countries most severely devastated by the HIV
epidemic. It is estimated that at the end of 2007 there were approximately 5.7 million
people living with HIV in the country, and this number grows daily [1]. The prevalence
among individuals aged 15-49 approaches 20%, demonstrating the impact of the virus on
the most productive members of society. An estimated 1,000 people die from AIDS in
South Africa each day, accounting for nearly half of all deaths in South Africa and 71%
of deaths among individuals aged 15-49 [2].
In addition to the enormous social burden of the disease, the HIV/AIDS epidemic
has had major economic consequences for South Africa. Disease-related morbidity and
mortality have led to losses in the labor market, reduced labor productivity, and reduced
exports [3]. Various indicators of human development have fallen sharply, as the country
struggles to mount a sufficient response against the epidemic. HIV consumes a
significant amount of national resources and health resources, hindering the ability of the
government to address other national needs.

1.2 Current interventions for HIV
Although the situation remains urgent, progress has been made in recent years by
a large coalition of non-governmental organizations, universities, international donors,
governments, and more. These agencies include the Global Fund to Fight AIDS,
Tuberculosis, and Malaria, the United States’ Emergency Plan for AIDS Relief, and the
World Bank’s Multi Country AIDS Projects. Changes in South African government
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policy have increased funding for provision of HIV treatment services, while also scaling
up other interventions including screening and health education. The Joint United Nations
Program on HIV/AIDS (UNAIDS) reports that in low- and middle-income countries,
28% of adults with advanced HIV infection were receiving antiretroviral therapy in 2007
[1]. The number of HIV positive pregnant women receiving antiretroviral therapy for
reduction of mother to child transmission increased to 66%. [4] Additionally, a survey
estimated that 100% of schools in South Africa included HIV/AIDS education in the past
year [4].
Although these statistics demonstrate improvement, substantial work remains. A
UNAIDS report estimated that $27 billion was needed for global HIV/AIDS prevention
between 2005 and 2007 but that only about $18 billion would be available [5]. Recent
trials for HIV vaccines and microbicidal gels have been very disappointing. With new
infections occurring every day, the need for HIV services is likely to continue to grow in
the most severely affected countries utilizing current strategies for treatment and
prevention.
While resources available to combat the epidemic in South Africa have
increased, policy makers must make difficult decisions about how to optimally distribute
a finite amount of resources among a number of potentially beneficial strategies.
Examples of treatment interventions include provision of antiretroviral medications for
infected patients and provision of prophylaxis against opportunistic infections. Preventive
interventions include HIV/AIDS education, distribution of condoms, prevention of
mother to child transmission, voluntary counseling and testing services (VCT), and
behavioral interventions for injection drug users such as needle-exchange and methadone
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maintenance programs. More recently, male circumcision has also been demonstrated to
be an effective tool for reducing heterosexual transmission of HIV among men in
Africa.[6-8]
Each of these interventions has direct and indirect costs and benefits that warrant
careful evaluation prior to implementation. Each intervention has the potential to improve
population health by preventing new HIV infections among uninfected individuals,
diagnosing infected individuals and providing a critical link to care, reducing diseaserelated morbidity and mortality, or some combination of the above. Whether the
potential benefits of each intervention warrant their expense is an important consideration
that should be evaluated prior to implementation. Moreover, by assessing the costs and
benefits of implementing multiple HIV interventions simultaneously, policymakers can
compare the relative trade-offs of each intervention and allocate limited resources for
HIV prevention and treatment more effectively.

1.3 Mathematical models of the HIV epidemic
Policy decisions about resource allocation have significant implications for
individuals infected with HIV, as well as those at risk for infection. In this setting,
mathematical models of HIV epidemics have become increasingly popular tools for
informing decisions about how to optimize limited resources to achieve certain goals.
Epidemic models can be used to estimate factors including HIV incidence, prevalence,
and mortality, in specified populations with varying degrees of granularity. Because of
the vast biological, social, and political complexities of HIV epidemics these models are
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intended to compare the potential gains from implementing particular interventions,
rather than predict the future course of the epidemic with certainty.
Multiple papers have been published recently that aim to use HIV epidemic
models to inform decisions about health policy and resource allocation in South Africa.
Granich et al used a novel epidemic model of HIV to analyze a strategy of widespread
screening for HIV with immediate initiation of antiretrovirals [9]. Their paper found that
their proposed strategy would accelerate the transition of the epidemic from an endemic
phase to an elimination phase, and that it could reduce HIV incidence and mortality to
less than one case per 1000 people by the year 2016 [9]. Andersson et al used a model to
examine the possible impact of a partially effective HIV vaccine on the heterosexual HIV
epidemic in South Africa [10]. Their paper found that even a modestly effective vaccine
could provide enormous benefits in preventing HIV infections, but also emphasized the
importance of concurrent educational programs to reduce risk behaviors. Another paper
found that migration patterns likely increased high-risk sexual behavior, facilitating HIV
transmission in South Africa [11]. Models have also been used to analyze how different
interventions might simultaneously impact the HIV and tuberculosis epidemics in South
Africa [12].
While each modeling study has limitations and must be at least partially reliant on
assumptions, these studies nevertheless add very meaningful analyses to debates about
optimal strategies for combating HIV epidemics. These models can be combined with
cost-effectiveness analyses to provide another layer of useful information to decision
makers.
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1.4 Cost-effective analysis for HIV resource allocation
Cost-effectiveness analysis is a useful tool for helping healthcare decision makers
determine how to best allocate resources across a defined number of competing needs to
maximize health outcomes for a limited budget [13]. Many of the countries most severely
affected by the epidemic, such as those in sub-Saharan Africa, are among the most
resource-limited in the world. Given the urgency of the situation, policy makers must
often allocate resources with incomplete information, so predictive models that compare
the costs and benefits of competing health interventions are important tools for guiding
policy. Where information is incomplete, sensitivity analyses can offer a range of
possible outcomes based upon likely scenarios.
In earlier stages of the epidemic, cost-effectiveness analysis was used to inform
debate among academics and policy makers about how to distribute investment between
treatment and prevention programs for HIV in sub-Saharan Africa [14]. As prices for
antiretroviral therapies have declined, global funding has increased, and model sites have
demonstrated success in treating HIV in resource-poor settings, the debate has shifted
from a focus on treatment or prevention to a broader question of how to best structure
multifaceted HIV intervention programs. In this setting, cost-effectiveness analysis has
been used to compare the health benefits and associated costs of different interventions
and strategies. For example, recent studies on HIV disease management have used costeffectiveness analysis to compare the use of different antiretroviral regimens[15],
compare different methods of monitoring HIV[16], and evaluate when to best start
HAART [17]. Cost-effectiveness analysis has also been used as a tool to measure the
efficacy of different preventative interventions in sub-Saharan Africa, such as recent

9

research on male circumcision[18] and the widespread treatment of sexually transmitted
infections, which is thought to reduce the likelihood of HIV transmission [19].

1.4 Portfolio model of HIV interventions
While cost-effectiveness analysis has provided useful data to guide decision
making on strategies to combat HIV/AIDS in resource-poor settings, a limitation of most
studies is that they analyze a single intervention at a time, or directly compare two or
more interventions. In reality, strategies to combat HIV/AIDS will be multi-dimensional,
with a number of interventions operating simultaneously. Many of these interventions
may have synergistic effects which are not captured in analyses that examine single
interventions at a time. For example, it is plausible that the presence of free antiretroviral
medications will impact an individual’s willingness to obtain voluntary counseling and
testing (VCT) services and that access to these services may influence an individual’s
HIV risk behaviors [20]. Similarly, in some circumstances there are diminishing returns
of multiple simultaneous interventions. For example, one study may find that a certain
preventive intervention may prevent one million HIV infections, and another study may
find that a different intervention can prevent two million HIV infections. However, this
does not imply that the two interventions will prevent three million HIV infections
because the target populations often overlap, and because infectious disease transmission
occurs in a non-linear manner (i.e., the likelihood of contracting HIV depends on the
fraction of individuals who are also infected). Understanding how different interventions
may affect the same population simultaneously is a limitation of existing HIV epidemic
models.
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These examples highlight the need for models that can examine multiple
interventions for HIV/AIDS simultaneously. In her paper, Long describes a
mathematical model that can be used to assess the effectiveness and the costeffectiveness of a portfolio of HIV interventions. The model translates behavioral and
biological factors influencing HIV transmission and disease progression into meaningful
epidemic and economic outcome measures [21]. By altering the degree of each
intervention, this model can estimate epidemiological and economic outcomes under
different assumptions about clinical efficacy and individual behavioral responses to the
interventions.

1.5 Evaluation of HIV intervention portfolio in South Africa
We proposed to use Long’s intervention portfolio model to evaluate the
heterosexual HIV epidemic in South Africa. By instantiating the model with
epidemiologic data from South Africa, we evaluated how different portfolios of
interventions impact the local epidemic. We chose to focus on three different
interventions that have been shown to reduce new infections and improve the morbidity
and mortality among infected individuals: male circumcision, voluntary counseling and
testing (screening), and administration of highly active antiretroviral therapy. While
many other possible interventions exist, we chose to examine portfolios comprised of
these three since they are applicable to a generalized heterosexual HIV epidemic. Recent
papers have advocated for increased funding for each of these interventions as a possible
means of making a major impact on the epidemic [9]. Also, papers have called for the
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needs for more mathematical models of HIV epidemics to inform critical policy decisions
[9].
By using this model to examine how different portfolios of these interventions
impact the epidemic in South Africa, we can then test the following hypothesis: the most
effective and cost-effective strategy for improving the HIV heterosexual epidemic in
South Africa is to implement a diverse portfolio offering a combination of these three
interventions.

2. Methods
2.1 Overview
We applied a dynamic compartmental epidemic model for HIV in South Africa
which accounts for HIV transmission and disease progression for a generalized
heterosexual HIV epidemic. Although the original model described in Long’s paper can
account for transmission in certain high risk groups, for the purposes of this study, we
focused only on heterosexual transmission and ignored transmission via injection drug
use, homosexual contact, and from commercial sex workers (CSWs). We utilized the
model to evaluate different portfolios of HIV interventions, each of which included a
unique combination of three interventions: male circumcision, voluntary counseling and
testing, and administration of highly active antiretroviral therapies (HAART). For each
portfolio, we applied the model to estimate outcomes including HIV prevalence, new
infections, costs, health benefits, and incremental cost-effectiveness ratios. We evaluated
the cost of each strategy on these epidemic and economic outcomes, to compare the costeffectiveness of each portfolio relative to the status quo and the next-best alternative.
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2.2 Population
Our model divides the adult South African population, aged 15 to 49, into 30
compartments based on the following factors: gender, risk behavior, infection status
(uninfected, asymptomatic HIV, symptomatic HIV, or AIDS) identification status
(unidentified or identified), treatment status (receiving antiretroviral therapy or not),
circumcision status (circumcised or not). A schematic diagram of the compartmental
model is shown in Figure 1.
Individuals enter the model when they reach age 15 and exit the model at death or
upon maturation beyond age 50. The mortality rate for each compartment varies and is
based upon previously published demographic data [22] . The movement of individuals
between compartments is determined by transition probabilities based on the rates of
disease transmission and disease progression.
Disease-related mortality and disease progression rates for each compartment
were based upon previously calculated data [23]. Quality of life factors for the different
disease states were obtained from previously published sources [24] . These estimates
allow the model to calculate the overall gain in health benefits as a result of reduced
morbidity and mortality.
2.3 Disease States
Each disease stage is defined according to CD4 T-cell count where asymptomatic
HIV designates an individual who is HIV positive with a CD4 T-cell count >350
cells/mm3, symptomatic HIV designates an individual who is HIV positive and has a
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CD4 T-cell count between 200 and 350 cells/mm3, and AIDS designates an HIV positive
individual with CD4 T- cell count below 200 cells/mm3.

2.4 HIV Screening
Identification status denotes whether an individual is aware of his or her HIV
status. We assume that individuals learn of their HIV status through voluntary HIV
counseling and testing services (VCT), and that individuals who participate in VCT
reduce their annual number of sexual partners by 20%. Individuals who receive VCT and
test negatively for HIV remain identified as negative for two years before they transition
back into a state where their HIV status is unknown. At this point these individuals are
then eligible to be screened again.

2.5 HIV Treatment
The treatment for HIV is highly active antiretroviral therapy (HAART). We
assume that in South Africa, only individuals with CD4 T-cell counts less than 200
cells/mm3 are eligible to receive HAART, consistent with the World Health
Organization’s guidelines for resource limited settings [25]. HAART has been
demonstrated to reduce the HIV viral load in an individual and subsequently, to reduce
the infectivity of an individual and the probability that the individual will transmit HIV to
a sexual partner [26]. We assume that individuals receiving HAART experience a
reduction in sexual infectivity of 90%, although we varied this value in sensitivity
analysis. HAART also increases an individual’s life expectancy, and subsequently the
length of time they can potentially infect their partners. By using a dynamic model such
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as the one we developed, we can evaluate how these opposing effects can influence
epidemic outcomes. Financial costs and the quality of life benefits associated with using
HAART are also taken into account for cost-effectiveness analysis.

2.6 Male Circumcision
Our model also assumes that currently 40% of South African adult men are
circumcised, and that all adult men are capable of being circumcised. We assume
circumcision results in a 60% reduction in HIV acquisition for heterosexual males based
on previously published data.[6-8]

2.7 Disease transmission
Data on sexual behaviors were obtained from a number of sources. We used an
average of 2.0 sexual partners per year for both males and females, from the South
African Demographic and Health Survey[27]. We also assumed both males and females
use latex condoms during 30% of episodes of sexual intercourse[4], and that condoms are
90% effective in preventing transmission of HIV based upon previously published data
[28].
Since our model is focused on the heterosexual HIV epidemic in South Africa, we
only considered HIV transmission via heterosexual sexual contact and we ignored other
modes of transmission including homosexual transmission, transmission via
contaminated needles, and mother to child transmission. The annual probability of HIV
transmission from male to female and from female to male is based upon previously
published data. [10, 24] These probabilities are then adjusted for the three HIV disease
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states used in our model (asymptomatic HIV, symptomatic HIV, AIDS) and also for the
presence of interventions (VCT, HAART, circumcision).
Each of these stratifications allows for more precise modeling of an individual’s
likelihood of acquiring or transmitting HIV and we adjust model parameters for each
compartment accordingly.

2.8 Model Implementation
The model is represented by a system of ordinary differential equations to track
the number of people in each health state, or compartment, over time. We instantiated
the model based on population compartment sizes in 2007 and assumed a 20-year time
horizon.
Parameters for the model were obtained from a combination of published primary
and secondary data, calculations, and assumptions. Table 1 shows all input parameters
used in the model and their sources. Our model assumed a South African adult
population (defined as individuals aged 15-49) of 12,530,300 men and 13,464,600
women based upon South African census data. The HIV prevalence among these groups
was 16.1% for men and 19.6% for women. Men and women were separated into
compartments based on previously published sources, as shown in Table 1. Using the
mathematical programming language Matlab, we numerically solved the system of
equations for different HIV intervention portfolios in South Africa.
We began with a “base case” scenario that represented the current use of the
three interventions discussed, examined over a 20-year time horizon, and based on
available 2007 data. In this base case, we assumed that 28% of all South African adults
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with HIV and CD4 counts less than 200 cells/mm3 received antiretroviral treatment upon
becoming eligible, and an additional 5% entered treatment programs annually. We also
assumed that 25% of all South African adults were tested for HIV and received the test
results in the past two years. Finally, we estimated that 40% of adult males are
circumcised and that this percentage will remain relatively constant. Under these base
case assumptions, we then projected HIV prevalence, new HIV infections, and total costs
and health benefits (measured in quality-adjusted life years or QALYs) incurred in the
population, over the 20-year time horizon. For each intervention portfolio, we then
estimated the change in HIV prevalence, HIV infections prevented, incremental costs,
incremental health benefits, and the incremental cost-effectiveness ratio (ICER)
compared to the base case scenario.

2.8.1 HAART focused portfolios
To create different scenarios to compare to the base case scenario, we altered the
composition of the portfolio of interventions. First, we examined hypothetical scenarios
for changes in the percentage of HIV patients receiving HAART to explore how
strategies that favor treatment scale up may affect the epidemic in South Africa. For these
scenarios, the fraction of patients screened for HIV and the fraction of adult males
circumcised remained constant with the base case. We created two separate “HAARTfocused” scenarios. In the first scenario, we assumed that HAART access increases to
50% of the eligible HIV infected population (CD4 count <200 cells/mm3). We also
created an “optimistic” scenario to examine HAART scale-up in South Africa. In this
case, we assumed that HAART access increases to 75% coverage. Again, we assumed
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that the fraction of patients screened for HIV and the fraction of adult men circumcised
remained constant.

2.8.2 Screening Focused Scenarios
Next, we created scenarios that examined how intervention strategies that favored
increased HIV screening impacted epidemic outcomes. First, we created a “moderate”
screening scenario, where we assumed that 50% of the adult South African population
would be screened for HIV every two years. For these screening focused scenarios, we
held the percentage of South Africans receiving antiretroviral therapy, and the percentage
of South African men circumcised constant from the base case.

We also created an

additional “optimistic” screening focused scenario, where we assumed that 75% of the
adult South African population is screened for HIV every two years, and otherwise
followed the same assumptions as for the “optimistic” scenario.

2.8.3 Circumcision Focused Scenarios
Next, we evaluated scenarios that favored widespread male circumcision. In the
base case scenario, we assumed that 40% of the adult South African male population is
circumcised, and that this remains constant over the 20-year time horizon. This means
that each year as new fifteen year olds enter the adult population, we assume that 40% are
circumcised. In the first circumcision focused portfolio, we assumed that every year 10%
of the uncircumcised adult male population will become circumcised, in addition to the
40% background circumcision rate. In the second “optimistic” scenario, we increased the
marginal circumcision rate to 20%. For both of these scenarios we held constant the
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percentage of HIV infected individuals receiving antiretrovirals, and the percentage of
adults screened for HIV every two years.

2.8.4

Combination Scenarios
Finally, we evaluated different combinations of two or three interventions.. For

each combination we considered a “moderate” and “optimistic” scenario.
First, we evaluated portfolios that favored a combination of increased
antiretroviral administration and increased screening. In these scenarios we assumed that
the percentage of South African adult men who are circumcised stays constant at 40%. In
the moderate scenario, we assumed that 50% of eligible HIV infected individuals receive
antiretroviral therapy, and 50% of South African adults undergo HIV screening every two
years. In the optimistic scenario, we increased both interventions to 75% coverage. We
then evaluated portfolios that favor a combination of increased antiretroviral
administration and widespread circumcision, while maintaining only 25% HIV screening
rates. In the moderate scenario, we increased antiretroviral therapy coverage to 50%, and
increased the marginal circumcision rate to 10%. In the optimistic scenario, we increased
the fraction of individuals receiving each intervention to 75% and 20%, respectively. The
next combination of interventions favored increased screening for HIV and increased
male circumcision.. In these two scenarios, the percentage of eligible individuals on
HAART remained at 28%. In the moderate scenario, we assumed that 50% of adults are
screened for HIV every two years, and an additional 10% of uncircumcised men are
circumcised. In the optimistic scenario, these fractions increased to 75% and 20%,
respectively.
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Finally, we explored scenarios for portfolios which utilized all three interventions.
In the moderate scenario, we assumed that 50% of eligible HIV infected South Africans
receive HAART, 50% of adults are screened for HIV every two years, and 10% of
uncircumcised men undergo circumcision each year. In the optimistic scenario, the
fraction of individuals receiving each intervention increases to 75% (HAART), 75%
(screening), and 20% (male circumcision).
We used the Matlab software to solve for each of these 14 scenarios to estimate
how each portfolio affected the overall South African HIV epidemic, population-wide
health benefits and costs, and incremental cost effectiveness, relative to the base case
scenario.

2.9 Student Contribution
Robert Stavert contributed by performing epidemiological research, conducting
the literature review, gathering data on the South African HIV epidemic to be instantiated
in the model, discussing relevant clinical assumptions, developing the scenarios evaluated
by the model, and reviewing the results and conclusions. All of this work was performed
together with Elisa Long who created the original dynamic compartmental model used in
this analysis.

3. Results
In the base case scenario, we estimated that approximately 10.6 million people
would become newly infected with HIV in South Africa over 20 years. At the end of the
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20-year horizon, the HIV prevalence was 14.67% among men and 16.67% among women
(Figure 2).

3.1 HAART focused portfolios
The scenarios for HAART focused intervention portfolios resulted in the smallest
number of infections prevented, compared to the base case scenario. The moderate
HAART focused scenario prevented 114,000 HIV infections (1.1% of projected new
infections) compared to the base case, and the optimistic scenario prevented 242,000
cases (2.3% of projected new infections) over twenty years (Figure 3). The moderate
HAART focused strategy added 4.8 million QALYs, at a cost of $434 per QALY gained
(Figure 4), and the optimistic scenario added 10.3 million QALYs at a similar cost per
QALY gained (Figure 5). HIV prevalence among men declined modestly to 14.6% in the
moderate scenario and 14.4% in the optimistic scenario (Figure 2). Among women, these
values were 16.5% and 16.4% respectively. HAART’s minimal reduction on HIV
prevalence is in part due to infected individuals living longer as a result of treatment.
Therefore, it is important to include in our analysis a universal metric, such as qualityadjusted life years, to account for the effect of reduced mortality on health benefits.

3.2 Screening focused portfolios
The screening focused intervention portfolios prevented more infections than the
HAART focused portfolios, but were more costly. The moderate screening focused
portfolio prevented 824,000 infections (7.8% of projected new infections) compared to
the base case, and increased QALYs by 7.6 million at a cost of $433 per QALY gained
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(Figures 3 and 4). In the moderate scenario the HIV prevalence in 20 years was 13.19%
for men and 14.99% for women (Figure 2). In the optimistic scenario, 1,387,000
infections (13.1% of projected new infections) were prevented, adding 13 million
QALYs at a cost of $499 per QALY gained (Figures 3 and 5). Screening-focused
strategies offered a greater reduction in HIV prevalence than HAART-focused portfolios.
After 20 years, HIV prevalence decreased to 13.19 % (moderate scenario) or 12.2%
(optimistic scenario) among men and 15.0% (moderate scenario) or 13.9% (optimistic
scenario) among women (Figure 2).

3.3 Circumcision-focused portfolios
Among the portfolios focused upon a single intervention, the circumcisionfocused portfolios prevented the largest number of HIV infections. The moderate
scenario prevented 1,470,000 infections (13.8% of projected new infections), adding over
13 million QALYs for only $55 per QALY gained (Figures 3 and 4). HIV prevalence fell
to 11.1% in men and 14.1% in women at the end of the 20 years (Figure 2). Although
circumcision primarily benefits men through reduced HIV acquisition, HIV prevalence
notably decreases among women as well, due to reduced secondary transmission.
Preventing one male HIV infection also prevents infection among future female partners,
hence, HIV prevalence among women also decreased. The optimistic scenario was even
more successful with 2,188,000 infections prevented over 20 years, with a net gain in 19
million QALYs and a cost-effectiveness ratio of $62 per QALY gained (Figures 3 and 5).
HIV prevalence substantially decreased to 9.7% and 12.8% for men and women
respectively (Figure 2).
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3.4 Combination Portfolios
We first considered intervention portfolios that include implementing two of the
three interventions simultaneously. In general, the number of infections prevented for a
two-intervention strategy was less than the sum of implementing the interventions
individually. For example, under moderate assumptions, expanded screening prevented
824,000 infections and expanded circumcision prevented 1,470,000 infections. However,
a portfolio that implemented these programs simultaneously prevented only 2,160,000
infections (compared to 2,294,000 if implemented independently). We find a similar
result with QALYs gained: screening adds 7.6 million QALYs, circumcision adds 12.7
million QALYs, and the combination strategy adds 19.3 million QALYs. The benefits of
implementing programs simultaneously are non-additive because the target populations
for each intervention may overlap, and an infection cannot be prevented more than once.
These results illustrate the need for using a dynamic epidemic model to appropriately
evaluate the effects of multiple infectious disease interventions.
Finally, we considered portfolios that scaled-up efforts of all three interventions.
In the moderate scenario, this portfolio prevented 2,257,000 new HIV infections (21.2%
of projected new infections) and increased QALYs by 23 million at a cost of $251 per
QALY gained relative to the base case (and $484 relative to the circumcision-focused
strategy) (Figures 3 and 4). HIV prevalence decreased to 9.9% among men and 12.6%
among women (Figure 2). Under optimistic assumptions, this portfolio averted
3,414,000 HIV infections (32.1% of projected new infections), more than with any other
strategy (Figure 3). As expected, this strategy increased QALYs by the greatest amount
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(38 million) at a cost of $305 per QALY gained relative to the base case (and $561
relative to the circumcision-focused strategy) (Figure 5). The favorable costeffectiveness ratios are largely driven by the relative inexpensiveness of male
circumcision. This strategy also offered the greatest reduction in HIV prevalence after 20
years: 8.1% among men and 10.7% among women (Figure 2). These were the lowest
prevalence rates of all the scenarios examined.

3.5 Sensitivity Analysis
We used sensitivity analyses to further evaluate areas of our model where there is
a degree of uncertainty about the data or about future events. One such area is the impact
of VCT on behavioral risk reduction. In the base-case of our model, we assume that
individuals who undergo VCT reduce their number of sexual partners by 20%, as has
been done in previously published studies [24]. In order to test the sensitivity of our
findings to this assumption, we varied the risk reduction of individuals who undergo VCT
from a minimum, where individuals do not change their risk behaviors at all after VCT,
to a maximum where individuals reduce their sexual partners by 40% after VCT. All
intervention portfolios examined remain cost-effective, including the three-intervention
combination portfolio, when there is no change in risk reduction after VCT. Under these
circumstances, the cost-effectiveness of the screening focused portfolios decreases as the
ICER is $4,122, demonstrating the importance of the educational component of screening
interventions. As the effectiveness of VCT in reducing risk behaviors rises, programs that
use this intervention become relatively more cost-effective compared to the base case.
When risk reduction is 10% the ICER of the moderate screening-focused portfolio is
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$730, and when risk reduction is 40% the ICER of the moderate screening-focused
portfolio is $278. This finding again demonstrates the importance of adequately funding
screening programs so that individuals who undergo VCT can receive helpful education
about how to reduce the likelihood of acquiring HIV and transmitting it to a sexual
partner.
Sensitivity analysis was also used to consider the effect of increased sexual
activity among men who underwent circumcision. Studies have reported increases in
sexual risk taking behavior in populations where antiretroviral therapies become widely
available [29]. There is concern that this trend may also apply to areas where male
circumcision is applied as a preventive measure, although preliminary data indicates that
this is not the case [30, 31]. We examined scenarios where male circumcision results in
increased sexual activity from a range of 0% change in sexual activity to a 30% increase
in sexual activity in individuals newly circumcised. Our findings demonstrate that as
sexual activity increases, overall costs increase, HIV prevalence increases, and the
effectiveness of portfolios decrease. However, even in the most pessimistic scenario
where circumcision results in a 30% increase in sexual activity, the circumcision based
portfolio still remains very cost-effective and has an ICER of $216, compared to an ICER
of $55 when we assume 0% increase in sexual activity. Similarly, the ICER of the
moderate portfolio that combines all three interventions increases from to $251 from
$422. Thus, even in the event that circumcision leads to a substantial increase in sexual
activity, portfolios with circumcision-based plans remain highly cost-effective.
In our initial scenarios, we assumed that HAART reduces the sexual infectivity of
an individual by 90%. There is some uncertainty about the degree to which HAART
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reduces infectivity, and there is also likely to be some variance from individual to
individual depending on factors such as adherence, HIV genotype, and an individual’s
genotype. We varied the impact of HAART on infectivity from 90% in the base case to a
minimum of 50% reduction in infectivity. This analysis results in fairly minimal changes
in the overall costs and effectiveness of the portfolios studied. The ICER of a HAARTfocused portfolio decreases from $552 to $434 as reduction in infectivity changes from
50% to 90%. Similarly, the ICER of the portfolio comprised of a combination of three
intervention changes from $259 to $251. Portfolios that include expanding access to
HAART remain cost-effective even with only a 50% reduction in sexual infectivity
because of the significant health benefits accruing among infected individuals receiving
HAART. These findings demonstrate that the intervention portfolios are fairly robust to
changes in the impact of HAART on infectivity.

4. Discussion
In this study, we evaluated the costs, health benefits, and cost-effectiveness of
expanded HIV screening, increased HIV treatment, and/or increased male circumcision
using a dynamic HIV intervention portfolio model. Our results highlight the significant
opportunities that may exist to improve upon the current set of interventions aimed at
controlling the generalized HIV epidemic in South Africa. The base case scenario
projected that close to 11 million new HIV infections may occur in adults over a 20 year
time horizon. Our model can be applied to compare the relative costs and benefits of
implementing various combinations of these three interventions, which may help policy
makers allocate resources among competing interventions. Our results highlight the
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urgency of increasing select HIV interventions, in order to most effectively mitigate the
South African epidemic.
Of the portfolios that focused on a single type of intervention, the circumcisionbased portfolios were significantly more effective and less expensive than the portfolios
which scaled up antiretroviral treatment and screening for HIV. The cost of
implementing circumcision programs is relatively low compared to other interventions,
and circumcision is a single, safe event, if done in the appropriate healthcare setting, and
an inexpensive mechanism for reducing HIV transmission. This finding is consistent with
previous studies that have demonstrated that male circumcision is a highly cost-effective
tool in South Africa. One recent study found that “Male circumcision can lower health
system costs. This finding is robust across a wide range of plausible parameter input
values for South Africa, including lower effectiveness, higher costs, and lower HIV
incidence. This analysis also suggests that male circumcision is amongst the most
economically efficient of HIV prevention strategies in sub-Saharan Africa.”[18] In our
single intervention portfolios, the ICER of circumcision strategies was $55-$62,
compared to $433-$499 for screening- and HAART-based strategies, further supporting
the idea that widespread male circumcision should increasingly be considered as a
strategy in South Africa.
These findings also create opportunities for further research in this area.
Epidemic modeling could be used to identify specific subpopulations to target for the
most effective delivery of a circumcision campaign, for example men from particular age
groups, men from particular locations in the country, or men with particular risk factors.
The possibility of pursuing widespread circumcision as a prevention strategy also
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demands that further research be undertaken to understand the personal and social
meanings of this intervention in the variety of cultures and subcultures of South Africa.
Portfolios that used circumcision in combination with other interventions were
more effective in preventing HIV infections than strategies that used individual
interventions only, however they were also more costly. The HAART and circumcision
portfolios prevented 1.6 to 2.4 million HIV infections with an ICER of $151 to $177,
while the screening and circumcision portfolios prevented 2.2 million to 3.2 million
infections at an ICER of $209 to $262. These findings demonstrate that while pursuing
circumcision alone as a strategy may be effective, even further gains can be obtained by
using circumcision in conjunction with other interventions. However, as circumcision is
used with other interventions the overall costs of programs escalate.
Additionally, when circumcision is added to existing portfolios of interventions,
the portfolios become more effective and more cost effective. When the circumcision
intervention is added to the HAART portfolio, the number of infections prevented
increases substantially from 114,000-242,000 to 1.6-2.4 million, and the ICER decreases
from $434-$433 to $151-$177. A similar effect is noted when a circumcision
intervention is added to the screening portfolio. In that case, the number of new
infections prevented increases from approximately 824,000-1.4 million to 2.2 million-3.2
million. The ICER falls from $433-$499 to $209-$262. This finding suggests that adding
a widespread circumcision intervention to the treatment and screening interventions
currently in place may offer significant benefits.
In the final scenario created, we examined a strategy that used a combination of
all three interventions. This strategy was the most effective overall in averting HIV
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infections but with a slightly higher incremental cost-effectiveness ratio: $251-$305
relative to the base case (or $484-$561 relative to circumcision-focused strategies). The
World Health Organization suggests that health interventions are “very cost-effective” if
they cost less than gross domestic product (GDP) per capita, and “cost-effective” if they
cost less than three times GDP per capita [32]. Based on these guidelines, this particular
HIV intervention portfolio falls significantly below the WHO’s threshold.

These

findings again suggest that the largest number of infections is prevented with portfolios
that are multifaceted and that it is possible to avert large numbers of infections with
moderate increases in overall program cost.
Our study model and findings are limited by a number of factors. Because of
limited data, we did not stratify certain populations who may have a higher risk of
acquiring or transmitting the HIV virus than the general population. In particular, we do
not have separate compartments for commercial sex workers, intravenous drug users, or
men who have sex with men. Individuals in each of these groups may influence the
shape of the HIV epidemic in South Africa in ways that are unaccounted for in our
model.
A few studies have recently attempted to learn more about the HIV epidemic
among men who have sex with men in sub-Saharan Africa and found that as in other
regions of the world, African men who have sex with men also have sex with women
[33]. This means that men who have sex with men are likely to shape the heterosexual
HIV epidemic in South Africa. However, the extent of this influence is not clear.
Similarly, data on injection drug use behavior in South Africa are very limited,
but some information is beginning to emerge. According to a UNAIDS review, injection
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drug use is an increasingly important factor in HIV epidemics in the region, and one
study found 28% of drug users tested in South Africa to be HIV positive [34]. In
addition, in other areas of sub-Saharan Africa a majority of drug users interviewed were
found to share needles with other drug users, and were also found to be sexually active
[34]. As more data on these high risk groups become available, incorporation of this data
into our epidemic model will allow for more precise estimates of how these groups
influence the HIV epidemic in South Africa and the success and costs of different
interventions.
Our model is also limited by the ability of the model to predict future events. One
such area is projection of the use and costs of second line antiretroviral therapies.
Currently, the cost of second line therapies for HIV far exceeds cost for first line
therapies in South Africa. A recent WHO report found that the current prices for the most
common first line antiretroviral regimens in lower middle income countries fell in a range
from about $140 per patient per year to $380 per patient per year [35]. However, prices
for the most common second line antiretroviral therapies were in the range of about
$1300 to $2700 per patient per year [35]. Currently, South Africans on second line
antiretrovirals make up a small minority of South African patients on HAART. However,
as treatment plans are scaled up and more patients with HIV are treated with HAART, for
longer periods of time, the number of patients who must be treated with second line
HAART increases rapidly. Another WHO report estimates that approximately 3% of
patients receiving HAART, per year, must switch from first line to second line therapies,
as patients develop strains of HIV that are resistant to first line therapies, or because they
are unable to tolerate the toxicities of particular medications [36].
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Depending on how this is projected over time, the cost of second line therapies
has a major impact on the overall cost of scaling up treatment. One report estimates that
by the year 2010, second line antiretrovirals will make up 90% of the cost of providing
antiretroviral therapies to low and middle income countries [37]. Projecting the use and
costs of second line antiretrovirals in South Africa twenty years into the future is very
challenging, as the prices of second line antiretrovirals are a subject of debate and
negotiation between drug manufacturers, governments, and non-governmental
organizations. Although it is reasonable to predict that prices for second line
antiretrovirals in South Africa are likely to decline during the twenty year time horizon of
our model, the extent and timing of this decline is difficult to predict and significantly
impacts the cost of scaling up treatment. In the future, the model can be used to
demonstrate the effect of second line antiretrovirals on the overall cost of scaling up
antiretroviral therapy as prices for these therapies change and more data emerges about
antiretroviral switch rates.
Another opportunity to expand the data provided by our model would be to create
different scenarios depending on when HAART is initiated. In our model, HAART is
initiated only in for a percentage of patients whose CD4 T-cell count is below 200 cells/
mm3; patients with CD4 counts above 200 cells/mm3 are not candidates for HAART even
if they otherwise meet WHO recommendations for HAART initiation. Initiating HAART
earlier in the course of an individual’s HIV disease provides a greater opportunity to
reduce HIV-related morbidity and the likelihood of transmitting the virus to partners.
Future studies could examine how varying the criteria for HAART initiation impacts the
effectiveness and cost of the portfolios of interventions described in this study.
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5. Conclusions
In this paper we describe the results of a study that uses a deterministic computer
model to explore the impact of different portfolios of interventions on the adult
heterosexual HIV epidemic of South Africa. Our study finds that portfolios which
incorporate widespread circumcision as a preventive intervention are generally more
effective and cost-effective than other portfolios that exclusively focus on expanded HIV
screening and/or treatment with HAART. Portfolios that combine a scale up of voluntary
counseling and testing resources, scale of up antiretroviral administration, and
widespread circumcision campaigns were the most successful overall in reducing new
infections and adding QALYs over the 20-year time horizon explored. We also find that
the costs and benefits of implementing multiple HIV interventions simultaneously are
non-additive, and a dynamic epidemic model such as the one we have implemented is
necessary in order to accurately estimate the effect of compound interventions on
epidemic and economic outcomes. In the absence of a clinical trial offering a similar
amalgamation of interventions, a mathematical model is the best tool for estimating the
costs and benefits of a portfolio of HIV interventions. In this study, we included only
three interventions; however, our modeling framework could be extended to include
additional interventions (e.g., a preventative vaccine, microbicide, genetic therapy)
should they become available in the future.
While the findings of this paper are intended to inform debates and discussions
about the optimal use of limited resources to combat the HIV epidemic in South Africa,
there are multiple limitations inherent in a mathematical model. Mathematical models are
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limited by the quality of the data used to generate estimates, and are based upon events
which have happened in the past and may not be necessarily predictive of the future.
Mathematical models may also not sufficiently account for costs and benefits that
are difficult to quantify. For example, increasing the availability of HAART in South
Africa is likely to have significant societal benefits not accounted for in the metrics of our
model, such as an increased life expectancy for parents, greater social stability, and
greater productivity leading to economic gains. Despite these shortcomings, the findings
of this study can be helpful as policy makers face difficult choices in allocating resources
to combat the HIV epidemic in South Africa. We hope that in the future we can apply
this model to assess a variety of different HIV intervention portfolios in different settings.
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Table 1: Model Input Parameters, Values, Source
Parameter

Value

Source

Demographic Parameters
Total population (15-49 year olds)
Males
Females
HIV prevalence
Males
Females
Fraction of HIV-infected individuals
Asymptomatic HIV (CD4 >350)
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
Mortality rate (non-HIV-related)
Male
Female
Maturation rate
Male
Female
Entry rate (includes growth rate)
Male
Female

12,530,300
13,464,600

[38]
[38]

16.1%
19.6%

[38]
[38]

50%
30%
20%

[39]
[39]
[39]

0.028
0.028

[10]
[10]

0.0162
0.0185

[38]
[38]

0.0623
0.0587

[38], [34]
[38], [34]

0.01
0.02
0.45
0.11

[22]
[22]
[22],[40]
[22], [39]

Disease Parameters
Disease mortality rate
Asymptomatic HIV (CD4 >350)
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
AIDS (CD4 <200) on HAART
Disease progression rate
Asymptomatic HIV (CD4 >350)
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
AIDS (CD4 <200) on HAART
Quality-of-life factor
Uninfected
Asymptomatic HIV (CD4 >350)
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0.1745
0.2755
---

[22]
[22]

1.0

[41]

Parameter
Unidentified
Identified – First Year
Identified – Subsequent Years
Symptomatic HIV (CD4 200-350)
Unidentified
Identified
AIDS (CD4 <200)
Unidentified
Identified
Identified and on HAART

Value
0.91
0.84
0.89

Source
[42], [24]
[24], [43]
[24]

0.79
0.72

[24], [43], [44], [45]
[42]

0.72
0.72
0.82

[24]
[44], [45], [43]
[45]

0.05
0.08
0.10

[24], [10], [46]
[24], [10], [46]
[24], [10], [46]

0.10
0.15
0.20

[24], [10],[46]
[24], [10],[46]
[24],[10],[46]

2.0
2.0

[27]
[27]

30%
30%
90%

[47]
[47]
[10]

25%

[48]

2
35%

[27]
[48]

Sexual Behavior Parameters
Annual probability of HIV transmission per
sexual partnership (FHIV+ÆMHIV-)
Asymptomatic HIV (CD4 >350)
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
Annual probability of HIV transmission per
sexual partnership (MHIV+ÆFHIV-)
Asymptomatic HIV (CD4 >350)
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
Average number of sexual partners per year
Males
Females
Condom usage
Males
Females
Condom effectiveness

Screening & Identification Parameters
Fraction of uninfected population identified
(HIV-tested in past 2 years)
Identification duration if uninfected (years)
Fraction of infected population identified
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Parameter
Annual probability of symptom-based case
finding if infected
Symptomatic HIV (CD4 200-350)
AIDS (CD4 <200)
Reduction in sexual behavior due to
screening
Uninfected
HIV-Infected

Value

Source

0.1
0.2

[24]
[24]

20%
20%

[24]
[24]

28%

[34]

90%

[24], [9], [49]

40%
50%

[34], [48], [27]
[7], [6], [8]

Treatment Parameters
Fraction of eligible individuals receiving
HAART at CD4 <200
Reduction in sexual infectivity due to
HAART

Circumcision Parameters
Fraction of males circumcised
Reduction in HIV acquisition due to
circumcision (heterosexual males)

Cost Parameters (2008 USD)
Annual HIV-related healthcare costs
$574
$852
$4,257
$736
$856
$142
$74
$64
3%

Asymptomatic HIV (CD4 200-350)
Symptomatic HIV (CD4 >350)
AIDS (CD4 <200)
AIDS (CD4 <200) on HAART
Annual non-HIV-related healthcare costs
Annual cost of HAART
Cost of testing and counseling
Cost of circumcision
Annual discount rate
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[22]
[22]
[22]
[22]
[1]
[35]
[50]
[18]
[51]

Table 2: Benefits and Costs of HIV Screening, Treatment, and Male Circumcision in
South Africa
HIV
Incremental Incremental ICER relative to
Portfolio Strategy
Infections
Costs
QALYs
Base Case Next Best
Prevented (billions)
(millions)
HAART-focused
Moderate

113,656

$2.10

4.85

$434

Dominated

Optimistic

242,075

$4.45

10.28

$433

Dominated

Moderate

824,040

$3.30

7.62

$433

Dominated

Optimistic

1,387,800

$6.48

12.97

$499

Dominated

Moderate

1,470,789

$0.70

12.73

$55

$55

Optimistic

2,187,508

$1.20

19.31

$62

$62

Moderate

2,256,555

$5.89

23.45

$251

$484

Optimistic

3,413,878

$11.50

37.64

$305

$561

Screening-focused

Circumcision-focused

Combination

Under the base case, approximately 10.8 million HIV infections occur over 20 years.
Incremental costs and quality-adjusted life years (QALYs) are relative to the base case.
Incremental cost-effectiveness ratio (ICER) is relative to the base case or the next-best
alternative, assuming all strategies are either moderate or optimistic.
Combination portfolios include increased HAART, screening, and circumcision.
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Figure 1: Schematic Diagram of Intervention Portfolio Model
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Figure 2: HIV Prevalence in Men and Women by Intervention Portfolio

HIV Prevalence: Males
0.25

0.2
Base Case
HAART Focus
Screening Focus
Circumcision Focus
Combination

0.15

0.1

0.05

0

2008

2010

2012

2014

2016

2018

2020

2022

2024

2026

HIV Prevalence: Females
0.25

0.2
Base Case
HAART Focus
Screening Focus
Circumcision Focus
Combination

0.15

0.1

0.05

0

2008

2010

2012

2014

2016

2018

42

2020

2022

2024

2026

Figure 3: Percentage of HIV infections Averted Relative to Base Case
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Figure 4: Cost-Effectiveness Analysis and Efficiency Frontier for Moderate Scenarios

Cost- effectiveness Analysis (Moderate Scenarios)
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Figure 5: Cost-Effectiveness Analysis and Efficiency Frontier for Optimistic Scenarios
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